Literature DB >> 16428552

A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model.

Thomas Sycha1, Doris Samal, Boris Chizh, Stephan Lehr, Burkhard Gustorff, Peter Schnider, Eduard Auff.   

Abstract

Several in vitro and in vivo investigations have shown that botulinum toxin A (BoNT/A) can inhibit the release of substance P and excitatory amino acids. Recently, a marked antinociceptive effect of BoNT/A and inhibition of glutamate release was observed in an animal pain model with inflammatory sensitization. In the present study, we tested the antiinflammatory and antihyperalgetic effect of BoNT/A in a well-characterized human inflammatory pain model. Using a randomized, double-blind, paired study design, we compared the effects of 100 mouse units of BoNT/A versus pure saline. Thermal and mechanical pain testings and superficial skin blood flow measurements were performed at baseline, at 48 h (in normal skin), and at 72 h (in inflamed skin) thereafter. Ultraviolet B irradiation resulted in a local inflammation with significant primary and secondary hyperalgesia. However, despite the evidence of efficacy on sudomotor function, BoNT/A had no effect on pain measures in either normal or inflamed skin. Signs of inflammation and primary and secondary hyperalgesia were found to be unaffected by BoNT. We have confirmed that BoNT/A has no direct effect on acute, noninflammatory pain. Furthermore, despite highly promising data from animal research, we have not observed antiinflammatory or antinociceptive effects of BoNT/A in human inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428552     DOI: 10.1213/01.ane.0000194447.46763.73

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  20 in total

Review 1.  [Potential antinociceptive mechanisms of botulinum toxin].

Authors:  K R Aoki; J Francis; W H Jost
Journal:  Schmerz       Date:  2006-09       Impact factor: 1.107

Review 2.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

3.  Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study.

Authors:  Larissa Bittencourt da Silva; Ali Karshenas; Flemming Winther Bach; Sten Rasmussen; Lars Arendt-Nielsen; Parisa Gazerani
Journal:  Pain Res Manag       Date:  2014 May-Jun       Impact factor: 3.037

4.  Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt.

Authors:  Shafaq Sikandar; Ynette Gustavsson; Marc J Marino; Anthony H Dickenson; Tony L Yaksh; Linda S Sorkin; Roshni Ramachandran
Journal:  Eur J Neurosci       Date:  2016-05-19       Impact factor: 3.386

Review 5.  Updated perspectives on neurogenic thoracic outlet syndrome.

Authors:  Paul J Christo; Kai McGreevy
Journal:  Curr Pain Headache Rep       Date:  2011-02

6.  Botulinum toxin therapy for osteoarticular pain: an evidence-based review.

Authors:  Jasvinder A Singh
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-04-01       Impact factor: 5.346

Review 7.  Evidence based medicine on the use of botulinum toxin for headache disorders.

Authors:  W J Schulte-Mattler; E Leinisch
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

8.  Botulinum Toxin: Non-cosmetic Indications and Possible Mechanisms of Action.

Authors:  Uwe Wollina
Journal:  J Cutan Aesthet Surg       Date:  2008-01

9.  Is botulinum toxin useful in treating headache? No.

Authors:  Mark Obermann; Hans-Christoph Diener
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 10.  A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models.

Authors:  Guido van Amerongen; Matthijs W de Boer; Geert Jan Groeneveld; Justin L Hay
Journal:  Br J Clin Pharmacol       Date:  2016-07-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.